GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Individuals 65-and-up, particularly those with other health conditions, are among those most-at-risk for severe cases of RSV.

London Health Sciences Centre is now offering respiratory syncytial virus (RSV) vaccinations to patients who don't have a ...

Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency related to its COVID-19 vaccine supply agreement.

This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...

About 2.1% of antibiotic prescriptions over the study period were connected to RSV diagnoses, especially in seniors and ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Fortunately, there is a safe, effective vaccine. For several years ... But in 2022, after the pandemic precautions relaxed, cases of influenza and RSV surged. Now it appears whooping cough is back as ...

Among physicians in Washington state, high prescribers of opioids were 2.9 times more likely to be high prescribers of ...

Doctors say they are seeing an unusual spike in walking pneumonia cases in parts of Canada, particularly in kids, but their ...

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter. He will remain chief executive officer of the biotech company.